Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals, Inc. (TARS) had 17 insider filings in the last 90 days, with the most recent on 2026-06-29. The full record for TARS runs to 54 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying TARS stock?
No insider purchases of TARS were filed in the last 90 days.
How many insiders are selling TARS stock?
6 insider sales of TARS were filed in the last 90 days, totaling $2.45M.
Where can I see TARS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks TARS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow TARS insider buys?
Create a free InsiderAlpha account and press Watch on this page to add TARS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
